Mandeep Sahani, MD
Nephrology · Mesa, AZNPI 1811080633
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,790 of the $6,896 with a category attached, or 69.5%. Akebia Therapeutics Inc accounts for 69.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $5,116 and has fallen 93.6% since, to $329 in 2025.
Across 33 payments — averaging $208.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$5K
- AstraZeneca$656
- Outset Medical Inc$366
- Nxstage Medical, Inc.$300
- Abbott$254
- Bard Peripheral Vascular, Inc.$128
- plus $402 from 6 others
Across 534 payments — averaging $1760.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$329K
- Modernatx, Inc.$259K
- Bayer$107K
- Sanofi US Services Inc.$83K
- Travere Therapeutics, Inc.$66K
- Ardelyx, Inc.$29K
- plus $68K from 4 others
What the payments were for
- Consulting fees$4,79069%
- Food & beverage$2,10631%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 1 | $4,790 |
| AstraZeneca(2 entities) | 13 | $656 |
| Outset Medical Inc | 3 | $366 |
| Nxstage Medical, Inc. | 4 | $300 |
| Abbott | 2 | $254 |
| Bard Peripheral Vascular, Inc. | 1 | $128 |
| Novo Nordisk | 1 | $124 |
| Travere Therapeutics, Inc. | 2 | $112 |
| Amgen | 3 | $105 |
| Bayer | 1 | $22 |
| Fresenius USA Marketing, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$254
- NXSTAGE SYSTEM ONE$216
- COVERA$128
- WAINUA$125
- Ozempic$124
- RYBELSUS$124
- LIBERTY SELECT CYCLER$102
How this compares
$6,896 in reported general payments places this provider in the 85th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 36 | $129,960 |
| Sevelamer Carbonate | 188 | $25,084 |
| LokelmaSodium Zirconium Cyclosilicate | 34 | $18,517 |
| Lanthanum Carbonate | 14 | $16,687 |
| Calcium Acetate | 51 | $3,605 |
| Gentamicin Sulfate | 31 | $1,415 |
| Nifedipine ErNifedipine | 73 | $972 |
| Hydralazine Hcl | 44 | $695 |
| Losartan Potassium | 69 | $574 |
| Clonidine Hcl | 52 | $448 |
| Ondansetron OdtOndansetron | 21 | $306 |
| Amlodipine Besylate | 54 | $245 |
| Furosemide | 28 | $155 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 12 | $142 |
| Lisinopril | 44 | $126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $20 | $129,96036 claims |
| AstraZenecaLokelma | $656 | $18,51734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 259 nephrology providers in Arizona.
Other nephrology in Mesa
- Asad ChaudharyMesa$6K
- Kenneth BorenMesa$5K
- Randy CooperPeoria$597K
- Minesh RajpalPeoria$403K
- Umar WaheedPeoria$150K
- Amer KhanPeoria$71K
- Samer Bani HaniPhoenix$54K
- Aneesha ShettyTucson$34K
- Leslie ThomasPhoenix$22K
- Alexander NimriPhoenix$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.